Business Wire - June 24, 2003

June 27, 2003 will mark the ninth annual National HIV Testing Day, a day when all Americans are urged to get tested to determine their HIV status. The National Association of People With AIDS (NAPWA) created the campaign in response to the growing number of new HIV infections among specific populations in the U.S. According to the Centers for Disease Control and Prevention ("CDC"), an estimated 200,000 people in the United States currently have the HIV virus but may be unaware that they are infected. Because of its ease of use and convenience, OraQuick(R) can help increase access to early diagnosis and referral for treatment and prevention services, particularly in high-HIV prevalence settings.

OraSure has partnered with the following specific sites in observance of National HIV Testing Day, which will be offering free HIV testing with the OraQuick Rapid HIV-1 Antibody Test:

-- Whitman-Walker Clinic, Washington, D.C.

-- Our Common Welfare, Atlanta, Georgia

-- The County of Los Angeles, Department of Health Services, Office of AIDS Programs and Policy and the L.A. Gay and Lesbian Center, Los Angeles, California

-- Philadelphia AIDS Consortium, Philadelphia, Pennsylvania

-- Mosaic Family Services, Dallas, Texas

-- Indiana State Department of Health, Indianapolis, Indiana

-- Maricopa County Department of Public Health, Phoenix, Arizona

-- Nebraska Health and Human Services System, Lincoln, Nebraska

"We are honored to be working with so many dedicated organizations for National HIV Testing Day to help stem the spread of the HIV virus," said Mike Gausling, Chief Executive Officer of OraSure Technologies. "As the only FDA-approved, CLIA (Clinical Laboratory Improvements Amendments of 1988) waived, rapid point-of-care HIV-1 test, we hope OraQuick(R) will help increase the number of people who get tested and learn their HIV results. We will continue to work in partnership with local, state and national agencies to help make this happen."

OraQuick(R) is the first FDA-approved rapid, point-of-care test designed to detect antibodies to HIV-1 in finger-stick whole blood within approximately 20 minutes. OraSure received FDA approval of the OraQuick (R)test on November 7, 2002. On January 31, 2003, OraSure received a CLIA waiver for the test, permitting its use by more than 180,000 sites in the United States, including outreach clinics, community-based organizations and physicians' offices.

Interview Footage and B-Roll Available June 25

A satellite uplink with National HIV Testing Day interview footage and b-roll will be available via a satellite on Wednesday, June 25 at 2:00 pm EDT. Coordinates for the satellite uplink are:

Date: 6-25-03 Time: 14:00 - 14:15 ET Satellite: Telstar 4C/10 D/L Freq: 3900 (V)

National HIV Testing Day footage includes; clinical setting OraQuick HIV testing footage; Whitman-Walker Clinic footage; HIV Testing Counseling footage, and footage of the OraQuick test procedure.

Interview footage includes:

Sam Niedbala, Chief Science Officer, OraSure;

Donna Futterman, Director, Adolescent AIDS Program, Montefiore Hospital, NY;

Cornelius Baker, Executive Director, Whitman-Walker Clinic, Washington, D.C.;

Mick Ellis, Director of HIV Counseling and Testing, Whitman-Walker Clinic;

Claude Allen, J.D., Deputy Secretary of the U.S. Department of Health and Human Services (HHS);

Ambassador Jack Chow, M.D., Deputy Assistant Secretary for Health and Science, U.S. State Department;

William H. Gimson, III, Chief Operating Officer, Centers for Disease Control and Prevention; and

Wilfrido Aguilar, Project Coordinator, Whitman-Walker Clinic (in Spanish).

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies and diagnostic products, including immunoassays and other in vitro diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to various distributors, government agencies, clinical laboratories, physicians' offices, hospitals, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

CONTACT: OraSure Technologies, Inc.

Investor Contact:

Ronald H. Spair, 610/882-1820

Investorinfo@orasure.com, www.orasure.com

or

Media Contact:

William Bruckner, 610/882-1820, wbruckner@orasure.com

SOURCE: OraSure Technologies, Inc.

030624
BW030608

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .